Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 18
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
7/13/2007
 
First Published:
1/1/1998
1.
Phase II Study of Whole Body Hyperthermia Combined With Doxorubicin HCl Liposome and Fluorouracil in Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
UTHSC-MS-96205
NCI-V97-1356, NCT00003135
Last Modified:
8/29/2008
 
First Published:
10/25/2003
2.
Phase II Randomized Study of Tariquidar and Docetaxel in Patients With Recurrent or Metastatic Lung, Ovarian, Cervical Cancer, or Renal Cell Carcinoma (no longer accruing patients with ovarian or lung cancer as of 3/01/06)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI
NCI-03-C-0284
NCT00072202
Last Modified:
8/12/2008
 
First Published:
8/24/2005
3.
Phase II Study of Isotretinoin, Interferon alfa-2b, and Paclitaxel in Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Over 18
Other
CINJ-100101
CINJ-3390, CINJ-NJ1703, NCT00138151
Last Modified:
9/27/2008
 
First Published:
9/16/2005
4.
Phase II Study of Pelvic Exenteration in Patients With Recurrent Cervical Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Over 18
NCI
GOG-0222
GOG-0222, NCT00217633
5.
Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
No age specified
Other
HSC-MS-01-111
HSC-MS-01-111, NCT00178802
6.
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
06US03IMP-852A [Cooley]
MT2006-02, NCT00319748
7.
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
VEG105281
NCT00430781
Last Modified:
5/22/2008
 
First Published:
5/4/2007
8.
Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Treatment
Active
Any age
NCI
CINJ-3330
NCT00161187
9.
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
06-1098
GSK 107278, NCT00548418
10.
Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Not specified
Other
2007-0324
NCT00626561
Select All on One Page
1
2
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute